Aligos Therapeutics, Inc. (ALGS) Financials
ALGS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 153.9 million | 61.8 million |
2023-09-30 | 85.9 million | 31.0 million |
2023-06-30 | 106.1 million | 36.5 million |
2023-03-31 | 121.7 million | 37.0 million |
ALGS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -22.7 million | 2.6 million |
2023-09-30 | -20.3 million | 3.2 million |
2023-06-30 | -13.6 million | 3.2 million |
2023-03-31 | -22.4 million | 3.7 million |
ALGS Net Income
No data available :(
ALGS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 135.8 million | - | 11.1 million |
2023-09-30 | 70.4 million | - | 11.8 million |
2023-06-30 | 90.8 million | - | 12.4 million |
2023-03-31 | 103.5 million | - | 12.0 million |
ALGS Shares Outstanding
ALGS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 7000 | 22.3 million | 6.4 million | 775000 |
2023-09-30 | 12000 | 15.9 million | 6.4 million | - |
2023-06-30 | 7000 | 16.8 million | 9.2 million | - |
2023-03-31 | 7000 | 18.1 million | 8.5 million | - |
ALGS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 2.7 million | 775000 |
2023-09-30 | 3.2 million | 681000 |
2023-06-30 | 6.9 million | 769000 |
2023-03-31 | 2.7 million | 844000 |
ALGS
Price: $0.80
52 week price:
Earnings Per Share: -1.36 USD
P/E Ratio: -0.38
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 78576
Market Capitalization: 81.0 million